Abstract:Abstract Background Diffuse large B-cell lymphoma (DLBCL) is a genetically and clinically heterogeneous disease. The cell-of-origin (COO) classification subdivides DLBCL into the transcriptionally defined activated B-cell (ABC) and germinal center B-cell (GCB) subtypes. While RNA based methods are considered the gold standard to determine COO, they are rarely used in clinical routine due to logistical and methodological challenges. Alternatives include the immunohistochemistry-based Hans algorithm and classifiers to infer the COO subtype from DNA sequencing [Esfahani et al., Blood 2019]. Despite the undisputed value of these methods, the concordance with the gold standard RNA and their prognostic implication are limited. We have recently shown that expression of individual genes can be inferred from cfDNA fragmentation patterns using a method called EPIC-Seq (EPigenetic expression Inference from Cell-free DNA Sequencing) [Esfahani et al., Cancer Res. 2020]. We therefore reasoned that EPIC-Seq may improve COO classification compared to other non-RNA methods. Methods A gene expression model, using cfDNA fragmentation patterns, was trained using leukocyte RNA-sequencing and deep whole genome profiling of the plasma cell-free DNA of an individual with no evidence of circulating disease. The trained model takes two features into account to infer gene expression: 1. promoter fragmentation entropy (PFE), and 2. normalized coverage at the nucleosome-depleted region of a given transcription start site (TSS). We then used a capture panel targeting TSS specifically designed for EPIC-Seq. We selected genes based on their power to discriminate COO subtypes in tumor RNA sequencing [Schmitz et al., NEJM 2018]. We first developed a classifier to distinguish DLBCL cases from healthy plasma using the inferred gene expression. Moreover, we defined GCB and ABC signature scores as the average inferred expression of a set of 'GCB genes' (n=34) and 'ABC genes' (n=34), respectively. Finally, we defined the COO score as the difference between the GCB and ABC scores. To validate our assay and method, we profiled 71 plasma samples from 68 healthy individuals and 90 pretreatment plasma samples from patients with large B-cell lymphomas using EPIC-Seq. Results We first evaluated the performance of the EPIC-Seq classifier in distinguishing DLBCL cases from controls and achieved an AUC of 0.92 in a cross-validation setting (Fig 1a). We then compared the result of EPIC-Seq COO classifier with the genotype-based method previously developed in our group. We observed epigenetic scores to be significantly correlated with previously described mutation-based GCB scores (r=0.75, P=1E-5, Fig. 1b). When comparing to the Hans classification algorithm, we observed significantly higher GCB scores in cases classified as GCB by Hans as compared with non-GCB cases (Wilcox P=0.001, Fig. 1c). Comparing the prognostic power of epigenetic and mutation-based COO labels in previously untreated patients using univariate Cox regressions, the EPIC-Seq classifier better stratified event-free survival (EFS) with higher GCB scores being associated with favorable outcomes (n=70, EPIC-Seq: HR=0.13, P=0.033 vs CAPP-Seq: HR=0.95, P=0.62). Importantly, when binarizing patients into GCB and non-GCB cases by the median, patients with tumors classified as GCB had significantly longer EFS than non-GCB counterparts (log-rank P=0.013, Fig. 1d). The Hans algorithm, in contrast, failed to stratify patients for EFS, among patients analyzed by both immunohistochemistry and DNA genotyping (Fig. 1e). Finally, we profiled n=12 additional DLBCL cases by both RNA-sequencing and EPIC-Seq. Strikingly, we found EPIC-COO scores to be significantly correlated with RNA based GCB scores (r=0.84, P=6E-4, Fig. 1f) underscoring the concordance of EPIC-Seq based COO classification with a gold standard scoring system. Conclusions We here apply EPIC-Seq, a method to infer expression of individual genes from cfDNA fragmentation patterns, to classify DLBCL patients into COO subtypes. COO classification by EPIC-Seq outperformed both Hans and mutation-based methods with regards to outcome stratification and correlated well with RNA-based methods. Overall, these results suggest that EPIC-Seq has utility for noninvasive classification of DLBCL cell-of-origin subtypes and may help to overcome logistical and methodological challenges of RNA-based methods. Figure 1 Figure 1. Disclosures Shahrokh Esfahani: Foresight Diagnostics: Current holder of stock options in a privately-held company. Kurtz: Genentech: Consultancy; Foresight Diagnostics: Consultancy, Current holder of stock options in a privately-held company; Roche: Consultancy. Diehn: Foresight Diagnostics: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; CiberMed: Current holder of stock options in a privately-held company, Patents & Royalties; Illumina: Research Funding; Varian Medical Systems: Research Funding; BioNTech: Consultancy; RefleXion: Consultancy; AstraZeneca: Consultancy; Roche: Consultancy. Alizadeh: Gilead: Consultancy; Bristol Myers Squibb: Research Funding; Janssen Oncology: Honoraria; Celgene: Consultancy, Research Funding; Forty Seven: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; CAPP Medical: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Roche: Consultancy, Honoraria; Foresight Diagnostics: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Cibermed: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company.

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

DLBCL cell of origin typing and whole transcriptome analysis using single slides with HTG EdgeSeq.

Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a Qpcr-Based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues

Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing

Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform

Determining Clinical Course of Diffuse Large B-cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms

DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study